Crossmark

Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune Thrombocytopenia

Crossref DOI link: https://doi.org/10.1007/s12288-018-1061-7

Published Online: 2019-01-01

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Hu

Liu, Liu

Shu, Xinhui

Wang, Xiaoran

Song, Yongping
License Information

Text and Data Mining valid from 2019-01-01
More Information

Article History

Received: 8 September 2018

Accepted: 11 December 2018

First Online: 1 January 2019

Compliance with ethical standards

:

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below